A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.

J Nanobiotechnology · 2021 · PMC8697442 · PMID 34949180

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

moderately significantp < 0.01actually significant

*p < 0.05 was considered significant, **p < 0.01 was considered moderately significant) and ***p < 0.001 was considered highly significant.

also in 2,178 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.